DAWN2: from insights to action

The three global study partners to the DAWN2TM study are the International Diabetes Federation (IDF), the Steno Diabetes Center and International Alliance of Patients' Organizations (IAPO). Together with Novo Nordisk, these partners oversee and work in collaboration to support the DAWN2 study execution, dissemination and translation. Below three international diabetes experts each representing leadership for DAWN2 global study partners, reveal their considerations and observations on study outcome, relevance, methodology and how DAWN2 findings will impact community and worldwide ‘Call to Action’ plans for improvements in diabetes person-centred healthcare.

IDF, Steno Diabetes Center. IAPO